Integrating large-scale genotype and phenotype data

OMICS A Journal of Integrative Biology

Volumn 10, Issue 4, 2006, Pages 545-554

  Hernandez Boussard, Tina ^a   Woon, Mark ^a   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DATA ANALYSIS; DATA BASE; DNA SEQUENCE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN GENOME PROJECT; INFORMATION PROCESSING; PHARMACOGENETICS; PHARMACOGENOMICS; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS;

ANIMALS; DATABASES, GENETIC; GENOTYPE; HUMANS; PHENOTYPE;

EID: 33846598002     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2006.10.545     Document Type: Review

References (28)

1. AYERS, M., SYMMANS, W.F., STEC, J., DAMOKOSH, A.I., CLARK, E., HESS, K., et al. (2004). Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22, 2284-2293.
2. BONNEN, P.E., PE'ER, I., PLENGE, R.M., SALIT, J., LOWE, J.K., SHAPERO, M.H., et al. (2006). Evaluating potential for whole-genome studies in Kosrae, an isolated population in Micronesia. Nat Genet 38, 214-217.
3. BRINKMAN, R.R., DUBE, M.P., ROULEAU, G.A., ORR, A.C., and SAMUELS, M.E. (2006). Human monogenic disorders-a source of novel drug targets. Nat Rev Genet 7, 249-260.
4. BROWN, E.G., WOOD, L., and WOOD, S. (1999). The medical dictionary for regulatory activities (MedDRA). Drug Saf 20, 109-117.
5. CARGILL, M., ALTSHULER, D., IRELAND, J., SKLAR, P., ARDLIE, K., PATIL, N., et al. (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22, 231-238.
6. CARLSON, C.S. (2006). Agnosticism and equity in genome-wide association studies. Nat Genet 38, 605-606.
7. CLAYTON, T.A., LINDON, J.C., CLOAREC, O., ANTTI, H., CHARUEL, C., HANTON, G., et al. (2006). Pharmacometabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077.
8. CRAIG, D.W., and STEPHAN, D.A. (2005). Applications of whole-genome high-density SNP genotyping. Expert Rev Mol Diag 5, 159-170.
9. FIELDEN, M.R., PEARSON, C., BRENNAN, R., and KOLAJA, K.L. (2005). Preclinical drug safety analysis by chemogenomic profiling in the liver. Am J Pharmacogenomics 5, 161-171.
10. GANTER, B., TUGENDREICH, S., PEARSON, C.I., AYANOGLU, E., BAUMHUETER, S., BOSTIAN, K.A., et al. (2005). Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119, 219-244.
11. GARRAWAY, L.A., WIDLUND, H.R., RUBIN, M.A., GETZ, G., BERGER, A. J., RAMASWAMY, S., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
12. GRIFFIN, J.L. (2006). The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci 361, 147-161.
13. GUNDERSON, K.L., STEEMERS, F.J., LEE, G., MENDOZA, L.G., and CHEE, M.S. (2005). A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 37, 549-554.
14. GYORFFY, B., SERRA, V., JURCHOTT, K., ABDUL-GHANI, R., GARBER, M., STEIN, U., et al. (2005). Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24, 7542-7551.
15. GYORFFY, B., SUROWIAK, P., KIESSLICH, O., DENKERT, C., SCHAFER, R., DIETEL, M., et al. (2006). Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118, 1699-1712.
16. HERNANDEZ-BOUSSARD, T., KLEIN, T.E., and ALTMAN, R.B. (2006). Pharmacogenomics: the relevance of emerging genotyping technologies. MLO Med Lab Obs 38, 24, 26-30.
17. HIRAKAWA, M., TANAKA, T., HASHIMOTO, Y., KURODA, M., TAKAGI, T., and NAKAMURA, Y. (2002). JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res 30, 158-162.
18. INTERNATIONAL-HAPMAP-CONSORTIUM (2005). A haplotype map of the human genome. Nature 437, 1299-1320.
19. KENT, W.J., SUGNET, C.W., FUREY, T.S., ROSKIN, K.M., PRINGLE, T.H., ZAHLER, A.M., et al. (2002). The human genome browser at UCSC. Genome Res 12, 996-1006.
20. KLEIN, T.E., and ALTMAN, R.B. (2004). PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Pharmacogenomics J 4, 1.
21. NEED, A.C., MOTULSKY, A.G., and GOLDSTEIN, D.B. (2005). Priorities and standards in pharmacogenetic research. Nat Genet 37, 671-681.
22. POLLACK, A., COWEN, D., TRONCOSO, P., ZAGARS, G.K., VON ESCHENBACH, A.C., MEISTRICH, M.L., et al. (2003). Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97, 1630-1638.
23. SCRIVER, C.R. (2004). After the genome-the phenome? J Inherit Metab Dis 27, 305-317.
24. SHASTRY, B.S. (2006). Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6, 16-21.
25. SHERRY, S.T., WARD, M.H., KHOLODOV, M., BAKER, J., PHAN, L., SMIGIELSKI, E.M., et al. (2001). dbSNP: the NCBI database of genetic variation. Nucl Acids Res 29, 308-311.
26. SOLIT, D.B., GARRAWAY, L.A., PRATILAS, C.A., SAWAI, A., GETZ, G., BASSO, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
27. TATE, S.K., and GOLDSTEIN, D.B. (2004). Will tomorrow's medicines work for everyone? Nat Genet 36, S34-42.
28. WHETZEL, P.L., RYAN R. BRINKMAN, R.R., CAUSTON, H.C., FAN, L., FOSTEL, J., FRAGOSO, G., et al., and members of the communities collaborating in the Fugo Project (2006). The development of FuGO-an ontology for functional genomics investigations. OMICS 10, 199-204.